1 Min Read
Feb 9 (Reuters) - Taigen Biopharmaceuticals Holdings Ltd :
* Says positive result of phase two clinical trial of anti-hepatitis C virus new drug TG-2349
Source text in Chinese: goo.gl/sWa1nM
Further company coverage: (Beijing Headline News)
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2017 Reuters. All Rights Reserved.